Douglas J. Manion
Pres and CEO at Aclaris Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Aclaris Therapeutics Inc., 3 years.
Aclaris Therapeutics Inc.
Director · Pres and CEO
Chief executive roles
Aclaris Therapeutics Inc.
· Pres and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 1, 2024 | Aclaris Therapeutics Inc. | Option exercise | +27,000 | — | — |
| Jan 1, 2024 | Aclaris Therapeutics Inc. | Shares withheld for tax | −9,125 | $1.05 | $9,581 |
| Aug 1, 2023 | Aclaris Therapeutics Inc. | Option exercise | +15,575 | — | — |
| Aug 1, 2023 | Aclaris Therapeutics Inc. | Shares withheld for tax | −4,437 | $9.81 | $43,527 |
| Mar 17, 2023 | Aclaris Therapeutics Inc. | Open-market purchase | +6,300 | $7.86 | $49,518 |
| Mar 9, 2023 | Aclaris Therapeutics Inc. | Open-market purchase | +6,500 | $7.74 | $50,310 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.